Clinical Trials

10 enrolled 17 charts

Lung Neoplasms

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

73 enrolled 12 charts

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07415005 2026-02-17

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

30 enrolled

Advanced Non-Small Cell Lung Cancer

NCT06007937 2026-02-05

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

56 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT06678555 2026-02-05

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Active not recruiting

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05297890 2025-12-23

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

70 enrolled

Phase 4 Active not recruiting

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT05144997 2025-12-17

Lorlatinib Continuation Study

76 enrolled

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

296 enrolled 28 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT04621188 2025-09-24

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

54 enrolled

Phase 2 Not yet recruiting

Non Small Cell Lung Cancer Metastatic

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

21 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04111705 2025-04-01

ORAKLE

Phase 2 Completed

23 enrolled

Non Small Cell Lung Cancer Metastatic

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Phase 4 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06893354 2025-03-25

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

20 enrolled

NSCLC

NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Enrolling by invitation

167 enrolled

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

NCT06858410 2025-03-05

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

36 enrolled

Adenocarcinoma of Lung

NCT04541706 2024-12-20

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4 Completed

100 enrolled 10 charts

Advanced Non-Small Cell Lung Cancer

NCT06690541 2024-11-15

COMLORLA

Not yet recruiting

100 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06682884 2024-11-12

NEOLORA

25 enrolled

Neoadjuvant Non-Small Cell Lung Cancer

NCT04127110 2024-11-05

ALKALINE

68 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung

NCT04800822 2024-10-22

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

53 enrolled

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT05014464 2024-09-20

ATPase

90 enrolled

364 enrolled 89 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

111 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03726333 2024-06-21

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Phase 1 Terminated

1 enrolled 3 charts

Lung Neoplasms, Neoplasms

NCT06378892 2024-04-23

ALK-PPL

45 enrolled

Non Small Cell Lung Cancer Metastatic

NCT06361589 2024-04-12

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Recruiting

200 enrolled

Phase 4 Not yet recruiting

ALK-positive Non-small Cell Lung Cancer

NCT06282874 2024-02-28

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

50 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06092086 2023-10-23

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

126 enrolled

ALK Positive Non-small Cell Lung Cancer

NCT02584634 2023-07-07

Javelin Lung 101

Phase 1/2 Terminated

43 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

ALK-positive NSCLC

NCT05167500 2023-03-30

LORLAPULM

118 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasm Metastasis

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

Phase 2 Unknown

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03439215 2021-07-19

PFROST

Phase 2 Unknown

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Phase 1/2 Unknown

96 enrolled

Lung Neoplasms, Recurrence

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Phase 2 Unknown

30 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03178071 2019-11-04

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

No longer available